Ruxolitinib Discontinuation at Conditioning Does Not Increase GVHD Risk in Myelofibrosis

Source: Pharmacy Times articles

Patients with myelofibrosis who stopped ruxolitinib on the first day of conditioning did not show higher rates of acute graft-versus-host disease (GVHD).
Read More